Public release date: 11-Jun-2012 [ | E-mail | Share ]

Contact: Susan Martonik smartonik@snm.org 703-652-6773 Society of Nuclear Medicine

Miami Beach, Fla.Finding a way to restore hair growth after substantial hair loss is something of an obsession worldwide. Investigators at the Society of Nuclear Medicine's 2012 Annual Meeting presented how stem cell research for the development of new hair follicles can be monitored with an optical imaging technique that uses bioluminescence, the same process that allows fireflies to light up.

There is a host of treatments available for hair loss, including creams and drugs, but these have not shown to be very effective for hair growth. Hair stem cells signal the actual regeneration of hair follicles and natural hair. A molecular imaging technique called bioluminescence is used to display processes at the cellular level. Bioluminescent signal is generated in specific chemical substances called substrates. These signals are easily recognized with very sensitive optical imaging systems that can see what is happening in the smallest placesin this case in hair stem cells.

"Hair regeneration using hair stem cells is a promising therapeutic option emerging for hair loss, and molecular imaging can speed up the development of this therapy," saysByeong-Cheol Ahn, M.D., Ph.D., professor and director of the department of nuclear medicine at Kyungpook National University School of Medicine and Hospital in Daegu, South Korea. "This study is the first study of hair follicle regeneration using an in vivo molecular imaging technique."

The current research involves grafting hair stem cells in animal models to investigate if they can grow and proliferate as normal cells do. The progress of hair stem cell therapy is non-invasivelytracked with bioluminescentreporter genes in specialized substrates. There are several bioluminescent reporter genes originating fromnot only fireflies, but also beetles, glowworms and other bioluminescent organisms. The strategy of using bioluminescent reporter genesis ideal for stem cell research, because bioluminescence works only in living cells.

In this study, researchers used bioluminescence imaging usingfirefly luciferase coupled with D-luciferin to monitor the engraftment of hair follicle stem cellscalled newborn fibroblastsin mice to track their viability and development into hair folliclesover time. Bioluminescence imaging was performed five times over the course of 21 days after transplantation of the stem cells.

Results of the study showed successful bioluminescence imaging forhair regeneration with hair stem cell transplantation, and new hair follicles were apparent on the surface of skin samples under microscope. More studies will have to be conducted before clinical trials could be initiated to verify whether this therapy would work for human hair regeneration.

###

Scientific Paper 74: Jung Eun Kim, Byeong-Cheol Ahn, Ho Won Lee, Mi-hye Hwang, Sang-Woo Lee and Jaetae Lee, Nuclear Medicine, Kyungpook National University School of Medicine, Daegu, Republic of Korea; Seng Hyun Shin and Young Kwan Sung, Immunology, Kyungpook National University School of Medicine, Daegu, Republic of Korea, "In vivo monitoring of survival and proliferation of hair stem cells in hair follicle regeneration animal model," SNM's 59th Annual Meeting, June 9, 2012, Miami Beach, Fla.

Continued here:
Bioluminescence imaging lights up stem cell therapy for hair growth

COLUMBUS, Ga. --

Every year, thousands of people like Noah Hein are diagnosed with blood cancers such as leukemia. A bone marrow or cord blood transplant can save their lives. The patients who do not have a donor in their family, depend on the National Marrow Donor Program and its Be the Match Registry. At this donor drive in honor of Noah , Jimmy Dawes was the 100th person to walk in and join the registry.

I saw the story and read the story about Noah and it touched my heart personally because my father lost a battle with leukemia when I was 14 so it kind of hit home for me personally, says Dawes.

After filling out the paper work, you simply swab your cheeks. Doctors will be looking for a tissue match, specifically the human leukocyte antigen or HLA. HLAs are proteins, or markers found on most cells in your body.

Roderick Gunn works for the National Marrow Donor Program.

If your tissue type comes up as a match, you would then be asked to submit a blood sample, so we could do confirmatory testing to confirm that you are indeed the best possible match, says Gunn.

Then, after passing a physical exam,the transplant is scheduled. There are two ways to give. Peripheral blood stem cells or PBSC and marrow. Gunn says PBSC is used 80 percent of the time but the doctor chooses the best donation method for the patient. PBSC is similar to giving blood at a blood drive.

And they separate the stem cells from your blood while at the same time returning your blood back to you.

In marrow donation, the donor is anesthetized and a special needle is inserted into pelvic bone, and the marrow withdrawn.

Gunn says the program needs more minorities. He says its harder to match minority patients with donors because the pool is so small. He says often misinformation can keep people away from the program. One myth is its going to cost the donor too much money.

Read more here:
HealthWatch:How to become a marrow donor

Scientists have paved the way for human bones to be replaced with new ones grown outside the body. Photo: iStockphoto

SCIENTISTS have grown human bone from stem cells in a laboratory, paving the way for patients to have broken bones repaired - or even replaced with new ones grown outside the body from their own cells.

Researchers started with stem cells taken from fat tissue. It took about a month to grow them into sections of fully formed living bone up to several centimetres long.

The first trial in patients is on course for later this year, by an Israeli biotechnology company that has been working with academics on the technology.

Advertisement: Story continues below

Professor Avinoam Kadouri, head of the scientific advisory board for Bonus BioGroup, said: ''We use three-dimensional structures to fabricate the bone in the right shape and geometry. We can grow these bones outside the body and then transplant them to the patient.

''By scanning the damaged bone area, the implant should fit perfectly and merge with the surrounding tissue. There are no rejection problems as the cells come from the patient.''

The technology, developed with researchers at the Technion Institute of Research in Israel, uses three-dimensional scans of damaged bone to build a gel-like scaffold that matches the shape.

Stem cells, known as mesenchymal stem cells, that have the capacity to develop into many other types of body cell, are taken from a patient by liposuction and are then grown into living bone inside a ''bioreactor'' - a machine that provides the conditions to encourage the cells to develop into bone.

Animals have already successfully received bone transplants, but in the latest study, the scientists were able to insert almost 2.5 centimetres of laboratory-grown human bone into a rat's leg bone, where it successfully merged with the remaining animal bone.

More here:
Fixing broken bones a growth industry

"We use three dimensional structures to fabricate the bone in the right shape and geometry. We can grow these bones outside the body and then transplant it to the patient at the right time.

"By scanning the damaged bone area, the implant should fit perfectly and merge with the surrounding tissue. There are no problems with rejection as the cells come from the patient's own body."

The technology, which has been developed along with researchers at the Technion Institute of Research in Israel, uses three dimensional scans of the damaged bone to build a gel-like scaffold that matches the shape.

Stem cells, known as mesenchymal stem cells, which have the capacity to develop into many other types of cell in the body, are obtained from the patient's fat using liposuction.

These are then grown into living bone on the scaffold inside a "bioreactor" an automated machine that provides the right conditions to encourage the cells to develop into bone.

Already animals have successfully received bone transplants. The scientists were able to insert almost an inch of laboratory-grown human bone into the middle section of a rat's leg bone, where it successfully merged with the remaining animal bone.

The technique could ultimately allow doctors to replace bones that have been smashed in accidents, fill in defects where bone is missing such as cleft palate, or carry out reconstructive plastic surgery.

Professor Kadouri said work was also under way to grow the soft cartilage at the ends of bones, which is needed if entire bones are to be produced in a laboratory.

Bone grafts currently involve taking bits of bone from elsewhere in the patients body and transplanting them to the area which is damaged to encourage healing.

More than 250,000 bone grafts are performed in the UK each year, including repairs to damaged jaws and the replacement of bone lost in operations to remove tumours.

Read the original here:
Human bones grown from fat in laboratory

by: Steve G. Jones, Ed.S

Obesity is defined as a body mass index (BMI) of 30.0 or greater. BMI is a ratio determined by weight and height. With a large percentage of Americans classified as being obese, research is showing the effects extra weight and obesity have on a person's overall health. Recent studies show that obese people have an increased risk of developing common kidney cancer, kidney stones, and an increased risk of having a stroke.

A study involving 1,640 participants studied the effects of weight on kidney cancer. The average age of patients was 62 and all participants had kidney tumors. The study showed that patients with a BMI of 30 or higher were 48% more likely to develop clear-cell renal cell cancer (RCC). With every 1 point increase in BMI, obese patients increased their odds of getting kidney cancer by 4%.

Out of all the participants, 67% of the obese patients had kidney cancer compared to 57% of non-obese patients. Researchers do not know why there is a link between obesity and kidney cancer. Researchers are looking into a secondary link involving diabetes, hypertension, hormonal changes, and decreased immune function. Read more…

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

Stuff.co.nz

Liquorice loaded with health benefits Stuff.co.nz Scientists at the Max Planck Institute for Molecular Genetics in Berlin, Germany identified a group of natural substances within liquorice root called amorfrutins. Testing on mice, the scientists found that the consumption of amorfrutins reduced blood ... and more »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

TIME

Paging Doogie Howser: 21-Year-Old Prodigy to Graduate from Medical School TIME He will graduate this week with an MD as well as a Ph.D. in molecular genetics and cell biology. He is the youngest student to receive an MD in the university's history, according to the Chicago Tribune. To say that Yano was an early bloomer is a bit ... Prodigy, 21, becomes youngest MD from Univ. of Chicagomsnbc.com 21-Year-Old Chicago Man Becomes an MDEveryday Health all 8 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

New York Daily News

Prodigy gets his MD at age 21; Sho Yano is preparing for his residency in ... New York Daily News Sho Yano, who was reading at age 2, writing at 3 and composing music at 5, will graduate this week from the Pritzker School of Medicine, where he also received a Ph.D. in molecular genetics and cell biology. Yano earned his undergraduate degree from ... Dr. Sho Yano: Chicago med graduate is Asian Doogie Howsernewjerseynewsroom.com Youngest MD: 21-year-old Sho Yano sets world record (PICS & Video)World Records Academy Former child genius graduates from medical school at age 21Los Angeles Times International Business Times all 27 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

The West Australian

Child prodigy earns medical degree at age 21 Detroit Free Press Sho Yano, who was reading at age 2, writing at 3 and composing music at 5, will graduate this week from the Pritzker School of Medicine, where he also received a Ph.D. in molecular genetics and cell biology, the Chicago Tribune reports. Child prodigy who licked college by 12 adds MD to his PhDMyFox Philadelphia all 298 news articles »

Source:
http://news.google.com/news?q=molecular-genetics&output=rss

The $3 billion California stem cell
agency, which hopes to generate income for the state through the sale
of stem cell therapies, is moving to make its profit-sharing rules
more friendly to business.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

California biotech companies chalked up
a zero in the latest funding round by the state's $3 billion stem
cell agency, although 14 tried to run a gauntlet that industry has
complained about for years.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Two directors of the $3 billion
California stem cell agency have popped up in the battle over the
anti-tobacco initiative on tomorrow's ballot in the Golden State.

"The...problem with Proposition 29
is its pigeonholing of the money for cancer research rather than for
immediate needs here in California that are absolutely dire. It’s
all well and good to say that cancer research benefits everyone, but
the real question is whether it should be the absolute top priority
for a state that can’t afford to keep its children fed or offer
them medical care in the here and now. 

"Lansing and Vuori say the fact
that Prop. 29 'fails to provide funding for schools, roads or
affordable housing' is irrelevant, because it was 'was never intended
to solve these problems.'

"In the context of the state’s
needs, this is a rather callous approach to take. Let’s spell out
why, so Lansing and Vuori won’t be so inclined to dismiss these
necessities of life so casually."

"That’s just the beginning of
what might be cut because the state needs money—and won’t be able
to lay its hands on the hundreds of millions of dollars that Lansing,
Vuori, and their research colleagues are angling for. They don’t
want voters to be reminded that there are competing demands for the
tobacco money, and they do so by failing to mention that they exist,
and also by presenting the spending on cancer research as the voters’
only choice. 

"It’s the only choice because
the promoters of Proposition 29 designed it that way. Advocates of
programs like this love to pass them in via voter initiatives because
they leave no room to measure them against alternative needs."

"Organizers argued that the tax would have
less chance of passing if voters thought it would go into the state
coffers, and said that their only goal here was cutting down on
smoking."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

7 June 2012

Bone Marrow Transplant Milestone

Today is a big day for the Waikato Hospital Haematology Department and equally big for consultant haematologist Dr Humphrey Pullon who established the transplant service there 20 years ago.

The first autologous bone marrow transplant was carried out at Waikato Hospital on 25 June 1992 and was today celebrated with a patient afternoon tea, which about 120 transplant recipients attended.

By the end of the month we will have performed 317 transplants in 301 patients over the past 20 years, said Dr Pullon.

The first patient went down to Wellington to have her stem cells collected and they were then driven back up to be stored here She is still alive, but was unable to attend today.

We did the stem cell collection of the second patient, who is sadly no longer alive, and our third patient was cured of Lymphoma as a result of his transplant.

The third patient was Lloyd Given of Tauranga who attended todays afternoon tea.

I would like to extend my thanks to Waikato Hospital, Humphrey and the oncologist at the time, Grant Trotter, he said.

The autologous bone marrow transplant process is a long and involved one.The cancer patient is treated and goes into remission or gets to a point where the cancer is well controlled.

View post:
Bone Marrow Transplant Milestone

By Anne Holden on June 7, 2012

Scientists at the UCSF-affiliated Gladstone Institutes have for the first time transformed skin cells with a single genetic factor into cells that develop on their own into an interconnected, functional network of brain cells.

The research offers new hope in the fight against many neurological conditions because scientists expect that such a transformation or reprogramming of cells may lead to better models for testing drugs for devastating neurodegenerative conditions such as Alzheimers disease.

Yadong Huang, MD, PhD

This research comes at a time of renewed focus on Alzheimers disease, which currently afflicts 5.4 million people in the United States alone a figure expected to nearly triple by 2050. Yet thereare no approved medications to prevent or reverse the progression of this debilitating disease.

In findings appearing online today in Cell Stem Cell, researchers in the laboratory of Gladstone Investigator Yadong Huang, MD, PhD, describe how they transferred a single gene called Sox2 into both mouse and human skin cells. Within days the skin cells transformed into early-stage brain stem cells, also called induced neural stem cells (iNSCs). These iNSCs began to self-renew, soon maturing into neurons capable of transmitting electrical signals. Within a month, the neurons had developed into neural networks.

Many drug candidates especially those developed for neurodegenerative diseases fail in clinical trials because current models dont accurately predict the drugs effects on the human brain, said Huang, who is also an associate professor of neurology at UCSF. Human neurons derived from reengineered skin cells could help assess the efficacy and safety of these drugs, thereby reducing risks and resources associated with human trials.

Huangs findings build on the work of other Gladstone scientists, starting with Gladstone Investigator, Shinya Yamanaka, MD, PhD. In 2007, Yamanaka used four genetic factors to turn adult human skin cells into cells that act like embryonic stem cells called induced pluripotent stem cells.

Also known as iPS cells, these cells can become virtually any cell type in the human body just like embryonic stem cells. Then last year, Gladstone Senior Investigator Sheng Ding, PhD, announced that he had used a combination of small molecules and genetic factors to transform skin cells directly into neural stem cells. Today, Huang takes a new tack by using one genetic factor Sox2 to directly reprogram one cell type into another without reverting to the pluripotent state.

Avoiding the pluripotent state as Drs. Ding and Huang have done is one approach to avoiding the potential danger that rogue iPS cells might develop into a tumor if used to replace or repair damaged organs or tissue.

Read this article:
Gladstone Scientists Reprogram Skin Cells into Brain Cells

SAN FRANCISCO Scientists at the UCSF-affiliated Gladstone Institutes have for the first time transformed skin cells with a single genetic factor into cells that develop on their own into an interconnected, functional network of brain cells.

The research offers new hope in the fight against many neurological conditions because scientists expect that such a transformation orreprogramming of cells may lead to better models for testing drugs for devastating neurodegenerative conditions such as Alzheimers disease.

This research comes at a time of renewed focus on Alzheimers disease, which currently afflicts 5.4 million people in the United States alone a figure expected to nearly triple by 2050. Yet there are no approved medications to prevent or reverse the progression of this debilitating disease.

In findings appearing online today inCell Stem Cell, researchers in the laboratory of Gladstone investigator Yadong Huang, M.D., Ph.D., describe how they transferred a single gene called Sox2 into both mouse and human skin cells. Within days the skin cells transformed into early-stage brain stem cells, also called induced neural stem cells (iNSCs). These iNSCs began to self-renew, soon maturing into neurons capable of transmitting electrical signals. Within a month, the neurons had developed into neural networks.

Many drug candidates especially those developed for neurodegenerative diseases fail in clinical trials because current models dont accurately predict the drugs effects on the human brain, said Huang, who also is an associate professor of neurology at UCSF. Human neurons derived from reengineered skin cells could help assess the efficacy and safety of these drugs, thereby reducing risks and resources associated with human trials.

Huangs findings build on the work of other Gladstone scientists, starting with Gladstone investigator Shinya Yamanaka, M.D., Ph.D. In 2007, Yamanaka used four genetic factors to turn adult human skin cells into cells that act like embryonic stem cells called induced pluripotent stem cells.

Also known as iPS cells, these cells can become virtually any cell type in the human body just like embryonic stem cells. Then last year, Gladstone senior investigatorSheng Ding, PhD, announced that he had used a combination of small molecules and genetic factors to transform skin cellsdirectlyinto neural stem cells. Today, Huang takes a new tack by using one genetic factor Sox2 to directly reprogram one cell type into another without reverting to the pluripotent state.

Avoiding the pluripotent state as Drs. Ding and Huang have done is one approach to avoiding the potential danger that rogue iPS cells might develop into a tumor if used to replace or repair damaged organs or tissue.

We wanted to see whether these newly generated neurons could result in tumor growth after transplanting them into mouse brains, said Karen Ring, UCSF Biomedical Sciences graduate student and the papers lead author. Instead we saw the reprogrammed cells integrate into the mouses brain and not a single tumor developed.

This research has also revealed the precise role of Sox2 as a master regulator that controls the identity of neural stem cells. In the future, Huang and his team hope to identify similar regulators that guide the development of specific neural progenitors and subtypes of neurons in the brain.

Original post:
Scientists reprogram skin cells into brain cells

June 8, 2012

Connie K. Ho for redOrbit.com

For the first time, scientists at Gladstone Institute have changed skin cells, imbued with a single genetic factor, into cells that can become a group of interconnecting, functional brain cells. The findings show that there may be options in combating neurological conditions. This transformation of cells would pave the way for better methods in testing drugs for neurodegenerative conditions like Alzheimers disease.

The research follows increased interest in Alzheimers disease. Currently, the disorder affects 4.5 million people in the U.S. and, by 2050, the number will have tripled. There are no medications to prevent or reverse Alzheimers Disease at this time.

The findings are published online at Cell Stem Cell and describe how the team of researchers transfer a single cell, known as Sox2, into mouse and human skin cells. Shortly, the skin cells became early-stage brain stem cells called induced neural stem cells (INSCs). The INSCs were able to self-renew and transmit electrical signals. The neurons were able to become neural networks within a month.

Many drug candidates especially those developed for neurodegenerative diseases fail in clinical trials because current models dont accurately predict the drugs effects on the human brain, commented Gladstone Investigation Dr. Yadong Huang, who is also an associate professor of neurology at the University of California, San Francisco (UCSF), in a prepared statement. Human neuronsderived from reengineered skin cellscould help assess the efficacy and safety of these drugs, thereby reducing risks and resources associated with human trials.

Huangs study was based off work done by Gladstone Investigator Dr. Shinya Yamanaka. Yanaka had four genetic factors become adult human skin cells then into embryonic stem cells, otherwise known as induced pluripotent stem cells (iPS cells). The cells can become almost any type of cell in the body. As well, last year, Gladstone Senior Investigator Dr. Sheng Ding found a combination of small molecules and genetic factors that could change skin cells into neural stem cells. These days, Huang uses one genetic factor, Sox2, to directly reprogram cell types without having to resort back to a pluripotent state.

We wanted to see whether these newly generated neurons could result in tumor growth after transplanting them into mouse brains, explained Karen Ring, UCSF Biomedical Sciences graduate student and the papers lead author, in the statement. Instead we saw the reprogrammed cells integrate into the mouses brainand not a single tumor developed.

The findings of the project have shown that Sox2 acts as a master regulator that maintains the identity of neural stem cells. In the future, Huang and his fellow researchers hope that they can identify similar regulators that can help the development of particular neural progenitors and subtypes of neurons in the brain.

If we can pinpoint which genes control the development of each neuron type, we can generate them in the petri dish from a single sample of human skin cells, noted Huang. We could then test drugs that affect different neuron typessuch as those involved in Parkinsons diseasehelping us to put drug development for neurodegenerative diseases on the fast track.

See more here:
Scientists Reprogram Skin Cells To Brain Cells

LEUVEN, BELGIUM--(Marketwire -06/08/12)- TiGenix (EURONEXT:TIG)

TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect

TiGenix (EURONEXT:TIG) announced today that its innovative cartilage repair therapy ChondroCelect has obtained national reimbursement in the Netherlands. The Dutch National Health Authority (NZa) has formally announced that ChondroCelect is to receive national reimbursement retroactively per January 1, 2012. Previously ChondroCelect was made available in the Netherlands under a risk-sharing scheme.

"We are delighted with the decision of the NZa to reimburse ChondroCelect, and look forward to working with Dutch orthopedic centers of excellence and health insurers to routinely make this breakthrough therapy available to the right patients in the Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch clinicians and scientists have been instrumental in ChondroCelect's development and four Cartilage Expert Centers in the Netherlands have already gained extensive experience with the procedure. After having obtained national reimbursement in Belgium last year, this constitutes another major step in improving patient access to this innovative therapy. We remain optimistic that we can obtain national reimbursement in other European countries later this year."

About TiGenix

TiGenix NV (EURONEXT:TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

About ChondroCelect

ChondroCelect is the first and currently only cell therapy that has been granted market authorisation by the European Union in accordance with the Advanced Therapy Medicinal Product regulation EC1394/2007. For more information, including the European Public Assessment Report (EPAR), prescribing information, and the Summary of Product Characteristics (SPC) please visit the European Medicines Agency (EMA) website at http://www.ema.europa.eu.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

Follow this link:
TiGenix: National Reimbursement in the Netherlands Obtained for Breakthrough Cartilage Therapy ChondroCelect(R)

CLEARWATER, FL--(Marketwire -06/08/12)- Biostem U.S., Corporation, (HAIR) (HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, today reported that it has engaged Acropolis Inc. http://www.acropolisinc.com, a full-service advertising agency located in Orlando, Florida, to lend their expertise in brand building, marketing, and advertising development and placement.

Biostem Chief Executive Officer Dwight Brunoehler stated, "After several months of interviewing prospective agencies, we have come to the conclusion that Acropolis is the one to assist us in executing our plans. Their notable work in multiple media areas is impressive, to say the least. Their client list including The University of Florida, Arby's Restaurants, and the City of Orlando, speaks for itself."

Acropolis Principal, Scott Major, said, "This is a great fit for Acropolis. Our entire team loves the Biostem business approach in the incredible field of regenerative medicine. The hair re-growth field in which we will be marketing the Biostem technology is enormous. We are pleased to be a part of Biostem's expansion."

About Biostem U.S. CorporationBiostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S., Corporation is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

For further information, contact Fox Communications Group at 310-974-6821, or view the Biostem website at http://www.biostemus.com.

Read the original:
Biostem U.S., Corporation Engages Acropolis Agency to Assist in Implementing Its International Marketing Plan

07-06-2012 07:52 Stem cells differ from other types of cells as they are unspecialized cells that are capable of differentiating into almost any type of specialised cells. Stem cells have the ability to replace the diseased and damaged tissue in the body, without the risk of rejection and any side effects. Therapy performed using stem cells is termed as "Regenerative medicine" and has many potential benefits in treating a wide variety of diseases and injuries. The journal is the major open access forum for translational research in stem cell therapies.

Go here to read the rest:
OMICS Group :: Journal of Stem Cell Research